Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Research analysts at assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXSGet Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ:ADXS opened at $0.64 on Friday. The firm has a 50-day moving average price of $0.74 and a two-hundred day moving average price of $0.78. Ayala Pharmaceuticals has a twelve month low of $0.51 and a twelve month high of $1.95.

Ayala Pharmaceuticals Company Profile

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.

See Also

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with's FREE daily email newsletter.